A phase II trial of belimumab, an anti-BAFF monoclonal antibody, in combination with rituximab/venetoclax is currently being investigated in patients with refractory or relapsed CLL (NCT05069051). The gene discussed is TNFSF13B; the disease is B-cell chronic lymphocytic leukemia.